SCHEMBL5074576

SCHEMBL5074576

CCN(CCO)CCCCN(C)c1ccnc2cc(F)ccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.49
CHRM2 P08172 2/20 0.48
CHRM4 P08173 2/20 0.48
CHRM5 P08912 2/20 0.48
ADRA2A P08913 2/20 0.48
CHRM1 P11229 2/20 0.48
ADRA2B P18089 2/20 0.48
ADRA2C P18825 2/20 0.48
CHRM3 P20309 2/20 0.48
KCNH2 Q12809 2/20 0.48
TMEM97 Q5BJF2 2/20 0.48
SIGMAR1 Q99720 2/20 0.48
ACE2 Q9BYF1 2/20 0.48
LMNA P02545 2/20 0.48
ADRA1D P25100 1/20 0.48
CGAS Q8N884 1/20 0.48
TLR9 Q9NR96 1/20 0.48
TLR7 Q9NYK1 1/20 0.48
SYK P43405 1/20 0.38
HRH3 Q9Y5N1 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1695452 0.92 CHRM2 (0.43) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL6433202 0.87 CDK1 (0.50) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL3229048 0.86 CDK1 (0.66) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1695273 0.86 CDK1 (0.47) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1695377 0.83 HRH3 (0.54) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1695307 0.80 CDK1 (0.73) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL3454269 0.80 CHRM2 (0.43) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL5074614 0.79 TMEM97 (0.50) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1695274 0.78 KDM4E (0.43) CDK1CHRM2CHRM4CHRM5ADRA2A
SCHEMBL1695848 0.78 CHRM2 (0.78) CDK1CHRM2CHRM4CHRM5ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026102297-A1 ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE Fulcrum Therapeutics, Inc. (US) 2026-05-15 WO disclosed
WO-2023043953-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY AVIDITY BIOSCIENCES, INC. (US) 2023-03-23 WO disclosed
EP-3898693-A1 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF Avidity Biosciences, Inc. (US) 2021-10-27 EP disclosed
EP-3735252-A2 HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF Avidity Biosciences, Inc. (US) 2020-11-11 EP disclosed
EP-3720448-A1 COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY Avidity Biosciences, Inc. (US) 2020-10-14 EP disclosed
EP-3691657-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF Avidity Biosciences, Inc. (US) 2020-08-12 EP disclosed
EP-3684376-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING Avidity Biosciences, Inc. (US) 2020-07-29 EP disclosed
WO-2020132584-A1 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF AVIDITY BIOSCIENCES, INC. (US) 2020-06-25 WO disclosed
WO-2019136180-A2 HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF AVIDITY BIOSCIENCES LLC (US) 2019-07-11 WO disclosed
WO-2019113393-A1 COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY AVIDITY BIOSCIENCES LLC (US) 2019-06-13 WO disclosed
WO-2019071028-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF AVIDITY BIOSCIENCES LLC (US) 2019-04-11 WO disclosed
WO-2019060775-A1 NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING AVIDITY BIOSCIENCES LLC (US) 2019-03-28 WO disclosed
EP-1581167-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS ALPHA RES GROUP LLC (US) 2008-10-29 EP disclosed
EP-1581167-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS Alpha Research Group, LLC (US) 2005-10-05 EP disclosed
WO-2004004660-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS ALPHA RESEARCH GROUP, L.L.C. (US) 2004-01-15 WO disclosed